Iranian Journal of Pathology

Delving into the Role of α-Smooth Muscle Actin as a Predictive Biomarker of Early Recurrence in Invasive Ductal Adenocarcinoma of Breast

Document Type : Letters to the Editor

Author

Seetu Palo

Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Bibinagar, Telangana, India

https://doi.org/10.30699/ijp.2024.2022442.3255
Abstract
Dear Editor,
I found the recent publication by Andrianto et al. (1) in the Iranian Journal of Pathology, titled "α-Smooth Muscle Actin as Predictors of Early Recurrence in Early-Stage Ductal Type Breast Cancer After Mastectomy and Chemotherapy," intriguing. This study, employing a cross-sectional immunohistochemical approach, investigates the significance of α-smooth muscle actin (α-SMA) as a potential biomarker for early recurrence in invasive ductal adenocarcinoma (IDC) of the breast. In the current era of precision medicine, it is apt to be on the look for novel biomarkers in predictive oncology, especially in breast cancer which remains one of the leading causes of cancer-related mortality in women despite scientific advancements. However, it's crucial to thoroughly understand the scientific methodology to fully grasp the paper's findings and utilize the same in clinical practice or research settings.

Keywords

α-Smooth muscle actin
biomarker
recurrence
ductal adenocarcinoma
breast

Subjects

  1. Andrianto A, Sudiana I, Suprabawati D. α-Smooth Muscle Actin as Predictors of Early Recurrence in Early-Stage Ductal Type Breast Cancer After Mastectomy and Chemotherapy. Iran J Pathol. 2024; 19(1): 67-74. [DOI:30699/ijp.2023.2004468.3126].
  2. Muchlińska A, Nagel A, Popęda M, Szade J, Niemira M, Zieliński J, et al. Alpha-smooth muscle actin-positive cancer-associated fibroblasts secreting osteopontin promote growth of luminal breast cancer. Cell Mol Biol Lett. 2022;27(1):45. [DOI:10.1186/s11658-022-00351-7] [PMID]
  3. Vathiotis IA, Moutafi MK, Divakar P, Aung TN, Qing T, Fernandez A, et al. Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer. Clin Cancer Res. 2021;27(22):6156-63. [DOI:10.1158/1078-0432]
  4. Kim S, You D, Jeong Y, Yu J, Kim S. W Nam, et al. TP53 upregulates α-smooth muscle actin expression in tamoxifen-resistant breast cancer cells. Oncology Reports, 2019;41(2):1075. [DOI:10.3892/or.2018.6910.]
  5. Shahriari-Ahmadi A, Arabi M, Payandeh M, Sadeghi M. The recurrence frequency of breast cancer and its prognostic factors in Iranian patients. Int J Appl Basic Med Res. 2017;7(1):40-3. [DOI:10.4103/2229-516X.198521] [PMID]
  6. Wadasadawala T, Kannan S, Gudi S, Rishi A, Budrukkar A, Parmar V, et al. Predicting loco-regional recurrence risk in T1, T2 breast cancer with 1-3 positive axillary nodes postmastectomy: Development of a predictive nomogram. Indian Journal of Cancer 2017;54(1): 352-7. [DOI:10.4103/ijc.IJC_178_17] [PMID]
  7. Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med. 2010;1(5):747-54. [DOI:10.3892/etm.2010.133] [PMID]
  8. Yekedüz E, Dizdar Ö, Kertmen N, Aksoy S. Comparison of Clinical and Pathological Factors Affecting Early and Late Recurrences in Patients with Operable Breast Cancer. J Clin Med. 2022;11:2332. [DOI:10.3390/jcm11092332] [PMID]
Iranian Journal of Pathology
Volume 19, Issue 3
Summer 2024
Pages 363-364

  • Receive Date 07 February 2024
  • Accept Date 13 May 2024

Home

Guide for Authors

Submit Manuscript

Contact Us